Advertisement
"As a result of our continued and projected growth, we have expanded andrealigned our management staff to best meet our business needs," said WayneAnderson, President and CEO. "Dr. Korner is exceptionally well qualified tofill this new role, as we continue our quest to achieve rapid new drugapprovals by identifying, improving and commercializing late-stage or marketedproducts in our clinical specialty areas."
Advertisement
Dr. Korner joins Ferring with a broad range of experience in medicalaffairs, clinical development, management and business development. Prior tojoining Ferring, Dr. Korner was Vice President of Medical Affairs, Women'sHealthcare at Bayer HealthCare Pharmaceuticals, where his group supported theU.S. Women's Healthcare business unit, and managed medical experts supportingPhase II and III development projects. He has also served as ExecutiveDirector of Medical Affairs, Female Healthcare at Berlex Laboratories, Inc.,and Senior Director of Clinical Research and Development, Women's Health andBone Repair for Wyeth Research.
Dr. Korner is a board certified obstetrician and gynecologist. Hereceived his M.D. from Loyola University, Stritch School of Medicine nearChicago. He also holds an M.B.A. from the Michael J. Coles College ofBusiness at Kennesaw State University in Georgia.
About Ferring Pharmaceuticals
Ferring Pharmaceuticals Inc., part of the Ferring Group, is a privatelyowned, international pharmaceutical company. Ferring's line of productsincludes: EUFLEXXA(R) (hyaluronic acid) for pain from osteoarthritis in theknee; BRAVELLE(R) (urofollitropin for injection, purified); MENOPUR(R)(menotropins for injection, USP); REPRONEX(R) (menotropins for injection,USP); Novarel(R) (chorionic gonadotropin for injection, USP) and ENDOMETRIN(R)(progesterone) Vaginal Insert for infertility. Ferring offers the Q-CAP(TM),the first needle-free reconstitution device, for use with its fertilitytreatments.
Other products include: ACTHREL(R) (corticorelin ovine triflutate forinjection) for the differential diagnosis of Cushing's syndrome; DESMOPRESSINACETATE in injectable and rhinal tube forms for the treatment of diabetesinsipidus and primary nocturnal enuresis; and PROSED(R) DS for the relief ofdiscomfort of the lower urinary tract.
The Ferring Group specializes in the research, development andcommercialization of compounds in general and pediatric endocrinology,urology, gastroenterology, obstetrics/gynecology, orthopaedics andinfertility. For more information, call 888-337-7464 or visitwww.FerringUSA.com.
SOURCE Ferring Pharmaceuticals Inc.